Remdesivir was developed by the famous American biopharmaceutical company Gilead Scientific Company, registered in/kloc-0 on June 22nd, 987, and headquartered in California, USA. Is a research-oriented biopharmaceutical company engaged in drug research and development and sales.
Remdesivir is a nucleoside analogue, which is being studied by Gilead Science.
It has antiviral activity. In HAE cells, the EC50 values of SARS-CoV and MERS-CoV are 74nM, and in delayed brain tumor cells, the EC50 value of murine hepatitis virus is 30nM.
Chinese name
Remdesivir
Foreign name
Remdesivir
molecular weight
602.576
structural formula
C27H35N6O8P
Interferon Canadian antiviral drugs cover the sky 360 Encyclopedia of Holy Market 360 Encyclopedia of Eternal Emperor 360 Latest News of Remdesivir Synthesis Route Fabira Virgil Encyclopedia
experimental data
The clinical trial of novel coronavirus's drug Remdesivir by Gilead will be launched in Beijing China-Japan Friendship Hospital on February 3rd. Gilead also issued a statement today, announcing that a randomized controlled trial is being conducted in cooperation with the health department of China to determine whether it is safe and effective to treat 20 19-nCoV infected people with Remdesivir.
Remdesivir has been proved to be active against virus pathogens of atypical pneumonia (SARS) and Middle East Respiratory Syndrome (MERS) in vitro and animal models. They also belong to coronavirus, which is very similar to 20 19-nCoV in structure. However, the clinical data of emergency treatment of Ebola virus-infected people with raloxivir are limited.
Remdesivir has not been approved for listing in any country, and its safety and effectiveness have not been confirmed. Remdesivir studies drugs, and there is no data of 20 19-nCoV. In the absence of any approved treatment plan, the therapist weighed the risks and benefits, and then made a request for medication. With the support of local regulatory authorities, Gilead provided the experimental drug Remdesivir for the emergency treatment of a small number of 20 19-nCoV infected people.
Drug use
Redixivir is a nucleoside analogue with antiviral activity. In HAE cells, the EC50 values of ARS-CoV and MERS-CoV are 74 nM, and in delayed brain tumor cells, the EC50 value of mouse hepatitis virus is 30 nM.
Patent problem
Regarding the application of a researcher from Wuhan Institute of Virology, Chinese Academy of Sciences for a patent against novel coronavirus, the company responded that Gilead developed Remdesivir and has patents in the United States, China and other parts of the world. In 20 16, Gilead applied for more patents for the application of coronavirus in Remdesivir in China and around the world. In China, the patent application for coronavirus application has yet to be approved.
In addition, Gilead said that it is too early to discuss any compulsory license or other types of licenses at this stage. Gilead's production and supply costs or financial returns have not been discussed with regulators.
On June 5438+1October 2 1 in 2020, China's invention patent (for the purpose of resisting 20 19 novel coronavirus) was declared, and it will enter major countries in the world through PCT (Patent Cooperation Agreement).
On February 25, 2020, He Zhimin, deputy director of China National Intellectual Property Administration, said at the press conference of the joint prevention and control mechanism in the State Council that Gilead Company applied for eight patents on the drug of raloxivir in China, of which three were authorized and five were under review. The scope of protection includes compounds, preparations and